首页> 外文期刊>Current medicinal chemistry >UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) inhibitors: A new class of antibacterial agents
【24h】

UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) inhibitors: A new class of antibacterial agents

机译:UDP-3-O-(R-3-羟基肉豆蔻酰基)-N-乙酰氨基葡糖脱乙酰酶(LpxC)抑制剂:一类新型抗菌剂

获取原文
获取原文并翻译 | 示例
           

摘要

The rapid increase of health-threatening infections by Gram-negative pathogens along with the emergence of multidrugresistant bacterial strains demands the development of novel antibiotics directed against the previously unexploited targets. One of the promising targets in Gram-negative bacteria is the zinc-dependent metalloamidase, UDP-3-O-(R-3-hydroxymyristoyl)- Nacetylglucosamine deacetylase (LpxC). LpxC catalyzes the first committed, second overall step in the biosynthetic pathway of lipid A. Thus, research on LpxC inhibitors as antibacterial agents has become an attractive field in the development of the novel antibiotic therapy of Gram-negative bacteria. In this review, we will summarize the recent progress in the studies on the structure, catalytic mechanism and regulation of LpxC and the current development of LpxC inhibitors.
机译:革兰氏阴性病原体威胁健康的感染迅速增加,以及多重耐药细菌菌株的出现,要求开发针对先前未开发目标的新型抗生素。革兰氏阴性细菌中有希望的靶标之一是锌依赖性金属酰胺酶,UDP-3-O-(R-3-羟基肉豆蔻酰基)-N乙酰基葡糖胺脱乙酰基酶(LpxC)。 LpxC催化脂质A生物合成途径中的第一个重要步骤,第二个总体步骤。因此,对LpxC抑制剂作为抗菌剂的研究已成为革兰氏阴性细菌新型抗生素疗法开发中的一个有吸引力的领域。在这篇综述中,我们将总结有关LpxC的结构,催化机理和调控以及LpxC抑制剂的最新研究的最新进展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号